299 related articles for article (PubMed ID: 27759595)
21. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.
Binder PS; Peipert JF; Kallogjeri D; Brooks RA; Massad LS; Mutch DG; Powell MA; Thaker PH; McCourt CK
Am J Obstet Gynecol; 2016 Dec; 215(6):766.e1-766.e9. PubMed ID: 27457116
[TBL] [Abstract][Full Text] [Related]
22. Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer.
Townamchai K; Berkowitz R; Bhagwat M; Damato AL; Friesen S; Lee LJ; Matulonis U; O'Farrell D; Viswanathan AN
Gynecol Oncol; 2013 Apr; 129(1):18-21. PubMed ID: 23262378
[TBL] [Abstract][Full Text] [Related]
23. A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC).
Chen L; Liu X; Li M; Wang S; Zhou H; Liu L; Cheng X
Cancer Med; 2020 Feb; 9(3):988-998. PubMed ID: 31846222
[TBL] [Abstract][Full Text] [Related]
24. Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study.
Halperin R; Zehavi S; Langer R; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2002; 23(4):300-4. PubMed ID: 12214728
[TBL] [Abstract][Full Text] [Related]
25. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?
Kwon JS; Abrams J; Sugimoto A; Carey MS
Int J Gynecol Cancer; 2008; 18(4):820-4. PubMed ID: 17892450
[TBL] [Abstract][Full Text] [Related]
26. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.
Nordström B; Strang P; Lindgren A; Bergström R; Tribukait B
Anticancer Res; 1996; 16(2):899-904. PubMed ID: 8687148
[TBL] [Abstract][Full Text] [Related]
27. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 1999 Sep; 74(3):385-94. PubMed ID: 10479498
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of pretreatment thrombocytosis in endometrial cancer: an Israeli Gynecologic Oncology Group study.
Tal O; Eitan R; Gemer O; Helpman L; Vaknin Z; Leytes S; Lavie O; Ben-Arie A; Amit A; Namazov A; Ben Shahar I; Atlas I; Bruchim I; Levy T
Int J Gynecol Cancer; 2021 Nov; 31(11):1437-1442. PubMed ID: 34725243
[TBL] [Abstract][Full Text] [Related]
29. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival.
Carcangiu ML; Chambers JT
Int J Gynecol Pathol; 1995 Jan; 14(1):30-8. PubMed ID: 7883423
[TBL] [Abstract][Full Text] [Related]
30. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract][Full Text] [Related]
31. The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry.
Mattes MD; Lee JC; Metzger DJ; Ashamalla H; Katsoulakis E
J Gynecol Oncol; 2015 Jan; 26(1):19-24. PubMed ID: 25310855
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma.
Lindahl B; Persson J; Ranstam J; Willén R
Anticancer Res; 2010 Sep; 30(9):3727-30. PubMed ID: 20944161
[TBL] [Abstract][Full Text] [Related]
33. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
Benedetti Panici P; Basile S; Maneschi F; Alberto Lissoni A; Signorelli M; Scambia G; Angioli R; Tateo S; Mangili G; Katsaros D; Garozzo G; Campagnutta E; Donadello N; Greggi S; Melpignano M; Raspagliesi F; Ragni N; Cormio G; Grassi R; Franchi M; Giannarelli D; Fossati R; Torri V; Amoroso M; Crocè C; Mangioni C
J Natl Cancer Inst; 2008 Dec; 100(23):1707-16. PubMed ID: 19033573
[TBL] [Abstract][Full Text] [Related]
34. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
[TBL] [Abstract][Full Text] [Related]
35. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
36. Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population.
Corey L; Cote ML; Ruterbusch JJ; Vezina A; Winer I
Am J Obstet Gynecol; 2022 Apr; 226(4):541.e1-541.e13. PubMed ID: 34736911
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of lymphovascular space invasion and nodal involvement in intermediate- and high-risk endometrial cancer patients treated with curative intent using surgery and adjuvant radiotherapy.
Narayan K; Khaw P; Bernshaw D; Mileshkin L; Kondalsamy-Chennakesavan S
Int J Gynecol Cancer; 2012 Feb; 22(2):260-6. PubMed ID: 22080878
[TBL] [Abstract][Full Text] [Related]
38. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
39. A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system.
Kim HJ; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
J Gynecol Oncol; 2013 Apr; 24(2):120-7. PubMed ID: 23653828
[TBL] [Abstract][Full Text] [Related]
40. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study.
Lin JF; Muñiz K; Sukumvanich P; Gehrig P; Beriwal S; Kelley JL; Edwards RP; Olawaiye AB
BJOG; 2016 Oct; 123(11):1846-52. PubMed ID: 26537059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]